Head and neck cancers are the seventh most common type of cancer worldwide. The chemotherapy drug cisplatin is the gold standard for treating these malignancies. However, more than 30% of patients, including some older adults and those with pre-existing kidney disease or hearing loss, cannot take cisplatin due to severe side effects. The monoclonal antibody cetuximab, while not as effective as cisplatin, is often used as an alternative in these patients. Durvalumab, an immune checkpoint inhibitor, has shown promise for treating a wide range of cancers, and has been proposed as a potentially safer and more effective option than cetuximab,...